NovoMedix, LLC is a biotechnology company developing novel small molecule multi-pathway modulators for the treatment of cancer, fibrosis, and inflammatory diseases. The firm's drug candidates are designed to modulate multiple biological pathways that are the critical drivers of diseases, and are generally inactive in normal tissues and housekeeping processes. This combination should provide potential drug candidates with wide therapeutic windows. NMX1 - the lead oral small molecule candidate - inhibits mTOR signaling and secretion of IL-11 to treat the tumor while activating AMPK to protect the heart in TNBC. The company is also advancing several candidates designed to treat fibrotic diseases, liquid tumors, and atopic dermatitis with timelines based on funding.
